tbuckley/cabot-search huggingface dataset:
Soundings: Death of a houseman
Authors: Colin Douglas
Journal: BMJ (2006)

For the whole of a six month house job half a lifetime ago, he was my friend, colleague, and doppelganger. The rota was grim, a one in two made worse by Saturday receiving: so no weekends off, ever. And once there was a minor misunderstanding and we were both dismissed with immediate effect by a surgical chieftain who was surprised to learn shortly afterwards that he couldn't do that sort of thing any more. We survived. Soon afterwards we were heading downstairs to the mess after another bad day, both whistling the Slaves' Chorus from Nabucco. The chief appeared round a corner, frowned even though we had stopped whistling, then wheezed his way on upwards. It was the nearest we came to rebellion.

With no particular effort or ambition, my friend had achieved the envied double: both house jobs in professorial units. His ward was well run and his handwriting legible. He was practical, straightforward, and sensible to a fault, and once gave me advice on my personal life that I sometimes still regret not having taken.

His patients liked him a lot. When I was called to his ward at night elderly women would ask me if he was going to be a general practitioner, because they wanted—as they put it—“to be on his panel.” He duly became a GP. I came across his patients from time to time in hospital over the decades, and yes, they all thought the world of him.

A few weeks ago his name appeared unexpectedly in the Scotsman: “Suddenly at home...” with details about a funeral the following Friday. For most medical funerals, being five minutes early is fine. It wasn't for his: a large church already full, so four of us—friends, colleagues, and messmates from that long gone teaching hospital world—stood together in the sun outside, in an extended congregation that heard the hymns only faintly, but in which it was all right to talk.

That helped. There was shock and grief, a good story or two from younger happier times, and an unexpected brush with survivors' guilt. We were all as old. He had been fit and active. We were still here and he was not. It wasn't fair. But as the last hymn faded and hundreds followed his coffin out into the sun, it was obvious again: his patients still thought the world of him.
The Queen Charlotte's Practice of Obstetrics.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder Cancer
Authors: E. Rintala, K. Jauhiainen, O. Alfthan, E. Hansson, H. Juusela, K. Kanerva, H. Korhonen, J. Permi, M. Sotarauta, T. Vaalasti, J. Viitanen, R. Usenius
Journal: European Urology (1991)
Case report of withdrawal dyskinesia associated with amoxapine
Authors: I Lesser
Journal: American Journal of Psychiatry (1983)

The antidepressant amoxapine is structurally related to the neuroleptic loxapine and can cause side effects related to hypothesized dopamine receptor blockade. This case of withdrawal dyskinesia after amoxapine discontinuation further demonstrates its potential for causing side effects associated with neuroleptics.
Regulation of Glucose Utilization in Tumors by a Stress-Modified Insulin: Anti-Insulin System
Authors: M WOODS, J HUNTER, D BURK
Journal: JNCI Journal of the National Cancer Institute (1955)

Regulation of Glucose Utilization in Tumors by a Stress-Modified Insulin: Anti-Insulin System Get access Mark Woods, Mark Woods Cytochemistry Section, Laboratory of Biochemistry, National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Jehu Hunter, Jehu Hunter Cytochemistry Section, Laboratory of Biochemistry, National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Dean Burk Dean Burk Cytochemistry Section, Laboratory of Biochemistry, National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 2, October 1955, Pages 351–404, https://doi.org/10.1093/jnci/16.2.351 Published: 01 October 1955 Article history Received: 07 February 1955 Published: 01 October 1955
Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis
Authors: C Jackisch, MJ Piccart, RD Gelber, M Procter, A Goldhirsch, E DeAzambuja, G Castro, M Untch, I Smith, L Gianni, J Baselga, N Al-Sakaff, S Lauer, E Mcfadden, B Leyland-Jones, R Bell, M Dowsett, D Cameron
Journal: Cancer Research (2016)

Abstract Background: Trastuzumab (T), a recombinant monoclonal antibody against HER-2 receptor, significantly improves overall (OS) and disease-free survival (DFS) in women with HER2 positive (HER2+) early breast cancer (EBC) when administered concurrent with or sequentially after adjuvant chemotherapy. Material and Methods: HERA (BIG 1-01) is an international, multicenter, phase III randomized trial involving 5102 women with HER2-positive (HER2+) EBC either nodal negative (tumor-size ≥ 1cm) or nodal positive. After completion of primary therapy, including surgery, chemotherapy and radiotherapy as indicated, patients (pts.) were randomized to T every 3 weeks for 1 yr, 2 years (yrs), or observation. Primary endpoint is DFS and secondary endpoints are OS and time to distant recurrence (TTDR). Here, we are presenting the HERA final analysis after 10 years of follow-up. Results: The clinical data cut-off for this final analysis of the HERA trial is June 2015. Data are being cleaned and final safety and efficacy analyses will be available for presentation at the meeting. Cardiac toxicity remained low and occurred mostly during the treatment phase. Citation Format: Jackisch C, Piccart MJ, Gelber RD, Procter M, Goldhirsch A, DeAzambuja E, Castro Jr G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, Mcfadden E, Leyland-Jones B, Bell R, Dowsett M, Cameron D. HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD5-01.
Educating staff to manage threatening paranoid patients
Authors: G A Di Bella
Journal: American Journal of Psychiatry (1979)

The threatening paranoid patient is one of the most frightening and difficult patients to treat. The author points out the need for all levels of hospital staff to become more adept at recognizing their own feelings, which often keep them from appropriately managing these patients. He summarizes several crucial points in teaching staff to cope successfully, dividing the process into diagnosis, management of one's emotions, and practice of appropriate therapeutic techniques.
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Authors: Roy Rampling, Sharon Peoples, Paul J. Mulholland, Allan James, Omar Al-Salihi, Christopher J. Twelves, Catherine McBain, Sarah Jefferies, Alan Jackson, Willie Stewart, Juha Lindner, Sarah Kutscher, Norbert Hilf, Lesley McGuigan, Jane Peters, Karen Hill, Oliver Schoor, Harpreet Singh-Jasuja, Sarah E. Halford, James W.A. Ritchie
Journal: Clinical Cancer Research (2016)

To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-specific therapeutic vaccine containing 11 tumor-associated peptides (TUMAP), identified on human leukocyte antigen (HLA) surface receptors in primary human glioblastoma tissue.
Intensive Chemotherapy in Poor-Prognosis Nonseminomatous Germ Cell Tumors of the Testis
Authors: J R Germá Lluch, M A Seguí Palmer, M A Climent Durán, R Blanco Guerrero, A Fernández Sagarra, H Villavicencio, F J Solé Balcells
Journal: European Urology (1992)
Aid to diagnosis of melanoma in primary medical care
Authors: D. De Berker
Journal: BMJ (1995)

Computerised data collection systems have not improved data collection EDITOR,-It is disappointing to learn that in the 10 years from 1984 to 1993 roughly 13% ofpatients with malignant melanoma living in Avon were not recorded by the South Western Regional Cancer Registry.'The disappointment is increased by the knowledge that a previous study performed in the same hospital showed that in 1974 the same cancer registry missed 8-19% of malignant melanomas in the Avon area.2The collection of data seems not to have improved in the past 20 years despite the introduction of computerisation.This is supported by a closer examination of the
Massive Obesity Simulating Lymphedema
Authors: Kim Eagle, Marlys H. Witte, Charles L. Witte
Journal: New England Journal of Medicine (1992)

Panel A shows massive obesity of the lower legs of a 64-year-old woman. Note the bilateral symmetric, nonpitting swelling of the legs with sparing of the feet, which can be mistaken for lymphedema. In Panel B, a radionuclide lymphangiogram taken 30 minutes after the injection of 99mTc-labeled human albumin demonstrates normal lymphatic vessels and regional lymph nodes with prompt cephalad migration of the radionuclide. In Panel C, transaxial (above) and coronal (below) magnetic resonance images confirm the presence of diffuse subcutaneous fat deposits without the accumulation of free fluid. The irregular high-intensity subcutaneous signals on the coronal images represent venous . . .
Letter to the editor: Commitment needed for the prevention of congenital rubella syndrome in Europe
Authors: T Derrough, S Bacci, P L Lopalco
Journal: Eurosurveillance (2012)

Preview this article: Letter to the editor: Commitment needed for the prevention of congenital rubella syndrome in Europe, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/17/10/art20106-en-1.gif
Overview: the right to treatment--comments on the law and its impact
Authors: A A Stone
Journal: American Journal of Psychiatry (1975)

The constitutional right to treatment has now become an accepted premise of litigation in the United States. It lacks only the imprimatur of the Supreme Court. The author presents a brief description of the history of right to treatment cases and comments on the problems and possibilities the law holds for psychiatry. He warns that psychiatric institutions must be aware of the costs and benefits of such litigation and must obtain skilled legal counsel to advise them of their rights and obligations. He calls on psychiatry as a profession to participate in right to treatment litigation and to attempt to shape legal standards so that future generations of psychiatrists can provide appropriate care to patients.
Abstract OT1-03-09: FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC)
Authors: C Saura, SJ Isakoff, I Calvo, D Patt, J Andersen, A Gonzalez-Martin, J Fisher, E Ciruelos, M Gil-Gil, L De la Peña, Y Choi, S Jia, S Singel, PH Patel, J Baselga, M Oliveira
Journal: Cancer Research (2016)

Abstract Background: TNBC often exhibits activation of PI3K/Akt signaling, associated with loss of PTEN expression, low INPP4B expression, and/or increased AKT3 amplification. Inhibition of the PI3K/Akt pathway in diverse cancers leads to radiosensitization and/or chemosensitization. Ipat is an oral, potent ATP-competitive small molecule inhibitor of all three isoforms of Akt. The combination of ipat with taxanes in preclinical models resulted in enhanced efficacy relative to either ipat or chemotherapy alone. In a Phase Ib clinical study, the combination of ipat with diverse chemotherapy regimens was well-tolerated and resulted in RECIST responses, particularly pts with tumors having PI3K/Akt activation. Methods: FAIRLANE is a randomized, double-blind, placebo controlled, multicenter, neoadjuvant Phase II study designed to estimate the efficacy of ipat combined with pac versus placebo combined with pac in women with Stage Ia  IIIa TNBC. Approximately 150 pts (Pts) will be enrolled, randomized in a 1:1 ratio, and stratified by PTEN status, node involvement, and tumor size. Pts will receive 3 cycles of ipat 400 mg or placebo orally once daily on Days 1 to 21 of each 28-day cycle, along with pac 80 mg/m2 every 7 days for a total of 12 doses. All pts will undergo pretreatment and Day 8 tumor tissue acquisition to evaluate pathway biomarkers. Following three cycles of treatment, pts will undergo surgery. The primary efficacy endpoint, pCR within the breast and axilla (ypT0/Tis ypN0) in all pts and in pts with PTEN low tumors, will be assessed by local pathology evaluation following completion of neoadjuvant therapy and surgery. Additional endpoints include objective response rate, safety, BCS rate, pharmacokinetics, and pathway biomarkers. Following surgical resection of primary tumor, pts are expected to continue post-operative treatment with a standard adjuvant chemotherapy regimen at physician's discretion. The study is open for accrual. Clinical trial information: NCT02301988. Citation Format: Saura C, Isakoff SJ, Calvo I, Patt D, Andersen J, Gonzalez-Martin A, Fisher J, Ciruelos E, Gil-Gil M, De la Peña L, Choi Y, Jia S, Singel S, Patel PH, Baselga J, Oliveira M. FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT1-03-09.
Abstract 2325: Endothelial Progenitor Cells Are Decreased In the Blood And In The Graft Of Heart Transplant Patients With Microvasculopathy
Authors: Elena Osto, Francesco Tona, Gianpaolo Fadini, Chiara Castellani, Ileana Baesso, Antonio Gambino, Carlo Agostini, Giuseppe Tarantini, Annalisa Vinci, Angelo Avogaro, Alida L Caforio, Gino Gerosa, Gaetano Thiene, Annalisa Angelini, Sabino Iliceto
Journal: Circulation (2008)

We assessed the relationship between peripheral blood progenitor cells (PCs), their incorporation into allografts and coronary microvascular function in heart transplant (HT) patients. Methods : PCs were determined by flow cytometry on the basis of the surface expression of CD34, CD133, and KDR antigens: CD34 + , CD133 + , CD34 + CD133 + , CD34 + KDR + , CD133 + KDR + , and CD34 + CD133 + KDR + . Biopsies at 2 different time points were examined. Immunoistochemistry for stem cells marker c-Kit, endothelial progenitor cells VEGFR-2, and CD34 was performed in serial sections in the all biopsies. Cells positive for each marker was counted in all biopsy area-section and the number obtained was corrected by area-section. Coronary flow velocity in the anterior descending coronary artery was detected at rest and during i.v. adenosine by transthoracic echocardiography. Coronary flow reserve (CFR) was the ratio of hyperaemic diastolic mean velocity (DMV) to resting DMV. CFR &lt; 2 was considered abnormal. CFR was measured in 29 pts (24 M, age at HT 50 ± 12 years) and was abnormal in 6 (group A) and normal in 23 (group B). Results : CFR was lower in group A (1.5 ± 0.1 vs 3.3 ± 0.8, p &lt; 0.0001). CD34 + KDR + , CD133 + KDR + , and CD34 + CD133 + KDR + cell count were lower in group A (p &lt; 0.05) (Figure ). Endothelial progenitor cells VEGFR-2 on biopsies tended to be lower in group A (p &lt; 0.06) and are related with circulating CD133 + KDR + , and CD34 + CD133 + KDR + (r = 0.752, p = 0.003 and r = 0.513, p = 0.052, respectively). Conclusion : Endothelial progenitor cells are decreased in the blood and in the graft of HT patients with microvasculopathy. Mobilization and engraftment of PCs in HT may be involved in the pathogenesis of allograft vasculopathy.
Abstract PD3-04: PAK-1 amplified breast cancer cell lines are preferentially sensitive to PAK inhibition with G-5555
Authors: CC Ong, E Blackwood, D Jakubiak, A Daemen, S Ramaswamy, C Heise, M Schmidt, L Sanders, TR Wilson, L Huw, C Ndubaku, J Rudolph, KP Hoeflich, L Friedman, T O'Brien
Journal: Cancer Research (2016)

Abstract The small GTP-binding proteins Rac1 and Cdc42 stimulate activity of the serine/threonine kinase p21-activated kinase-1 (PAK-1) to drive growth factor signaling networks and Ras-driven tumorigenesis. Genomic amplification and over-expression of PAK1 are prevalent in luminal breast cancer and correlate with poor clinical outcome. Here we use a novel and selective small molecule inhibitor, G-5555, of the group I PAKs (PAK1, 2, and 3) to evaluate the importance of PAK1 in promoting growth of PAK1 amplified breast cancer cells. Cell lines with amplification of PAK1 were found to be more sensitive to PAK1 inhibition than non-amplified cell lines. Additionally, reverse phase protein array (RPPA) was used to assess the effects of PAK1 inhibition on a wide range of signaling pathways in both amplified and non-amplified cell lines. Reduced levels of phosphorylation of MEK S298 was observed in all cell lines exposed to G-5555 irrespective of amplification status, consistent with PAK1 inhibition in these cell lines. However, modulation of this downstream PAK1 substrate did not correlate with inhibition of cell proliferation or induction of cell death. Cell lines that showed inhibition of proliferation in response to G-5555 also showed enhanced levels of cell death along with apoptosis. Moreover, G-5555 reduced tumor growth in the PAK1 amplified MDA-MB-175 xenograft tumor model. Finally, we compared the in vitro activity of G-5555 with palbociclib, a recently approved inhibitor of the cyclin-dependent kinases CDK4 and CDK6, in PAK1 amplified luminal breast cancer cell lines. Our data supports PAK1 as an attractive target in PAK1 amplified cells and tumors and suggests that inhibiting PAK1 rather than CDK4/6 in this context may be a more attractive therapeutic strategy. Citation Format: Ong CC, Blackwood E, Jakubiak D, Daemen A, Ramaswamy S, Heise C, Schmidt M, Sanders L, Wilson TR, Huw L, Ndubaku C, Rudolph J, Hoeflich KP, Friedman L, O'Brien T. PAK-1 amplified breast cancer cell lines are preferentially sensitive to PAK inhibition with G-5555. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD3-04.
Soundings: Pinot Noir powders
Authors: George Dunea
Journal: BMJ (1999)

In the early 1950s posters informed Parisians of the health risks of drinking wine. The Academy of Medicine had found it was definitely unhealthy to drink more than one litre of wine a day.

Since those halcyon days the dose deemed compatible with good health has been whittled down—to almost homoeopathic levels. Accordingly, the complications of the grape have often given way to those of the poppy, so that in some hospitals medical students have never seen delirium tremens and misdiagnose it as an acute variant of mad cow disease.

Worse still, even though drinking a glass of red wine a day has been claimed to improve endothelial function, the ingredients of de-alcoholised wine have been rumoured to achieve the same effect. While working at a meeting to improve my own endothelial function, I met a researcher who was using an ingredient called resveratrol to prevent cancer in mice—under the watchful eye of the Institutional Scientific Review Board, the Rodent Ethics Committee, the Department of Agriculture, the Food and Drug Administration, the Environmental Control Agency, the General Accounting Office, the Antifraud Police, the Evidence Based Medicine Squad, and the League against Duplicate Publication.

I learnt that in addition to resveratrol wine has other beneficial polyphenols and related compounds: catechin (reduced tumours by 40% in Californian mice); quercetin (inhibits growth of breast cancer cells); and other phenols that inhibit low density lipoprotein oxidation and platelet aggregation and may prevent atherosclerosis. Some scientists now think that the “French paradox” is all hooey and that Frenchmen (but not rats) will soon be in for it. Resveratrol, incidentally, antagonises oestrogen binding and induces cancer apoptosis; it may be purchased as a powder.

Distressed by having to swallow powders to restore my own flagging endothelial function, I was further discouraged by a letter in the Lancet. It reported a study in which many subjects could not tell red wine from white. The study came from Nuits St Georges; the subjects were presumably French and not intruders from Greater Shengen or Outer Euroland, which shows that the errors disseminated by the Academy of Medicine half a century ago have now come back to haunt us.
Analysis of Enzymatic Activities of Clones Derived From Variant Cell Lines Transformed to Malignant Cells in Tissue Culture
Authors: Dwight B. McNair Scott, Anna Marie Pakoskey, Katherine K. Sanford
Journal: JNCI Journal of the National Cancer Institute (1960)

Two cell lines, derived in vitro from one cell isolated from a culture of normal mouse tissue, were found in previous studies to differ in morphology, metabolism, and rate of growth to form malignant tumors in mice of the strain of origin (C3H). When cells of one line, designated low tumor-producing or “low,” were injected into mice, tumors developed slowly or not at all, whereas tumors developed rapidly from implants of the other cell line, designated high tumor-producing or “high.” Three clones established from single cells of the low line and one clone from the high line have been investigated to determine whether there is any correlation between activities of some enzymes metabolizing glucose oxidatively and the rate of growth into tumors when cells are implanted in mice. The activities of the enzymes hexokinase, glucose-6-phosphate dehydrogenase, and phosphogluconate dehydrogenase have been determined in the whole cells and in cell-free extracts of the cells. The mean specific activities of all 3 enzymes were very similar for 2 of the clones from the low line. The third of the clones from the low line that differed in certain other characteristics had the same phosphogluconate activity, a 50 percent higher hexokinase activity, and twice the glucose-6-phosphate dehydrogenase activity. The clone derived from the high line had nearly 3 times the hexokinase activity, 4 times the glucose-6-phosphate dehydrogenase activity, and 5 times the phosphogluconate dehydrogenase activity compared with 2 of the low-line clones. The differences between the derivative clones from low and high lines are even greater when the enzyme activities of the whole cells or the extracts are calculated per cell.